Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-016053

EVP and Chief Medical Officer sold 3,881 shares at $45.25 ($175,615)

  • EVP and Chief Medical Officer acquired 2,663 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bedrosian Camille L EVP and Chief Medical Officer 2023-03-01 Grant or award +2,663 50,601 D: show line 1 in the form
Bedrosian Camille L EVP and Chief Medical Officer 2023-03-01 Sale −3,881 $45.25 $175,615 46,720 D: show line 2 in the form
Open-market sales · 3,881 sh · avg $45.25 · $175,615
Loading xslF345X03/doc4.xml…